Insider Selling: Martin Goldwyn Sells 1,500 Shares of Hi-Tech Pharmacal Co. Stock (HITK)
Hi-Tech Pharmacal Co. (NASDAQ:HITK) Director Martin Goldwyn unloaded 1,500 shares of the company’s stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $43.10, for a total value of $64,650.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
A number of research firms have recently commented on HITK. Analysts at Zacks upgraded shares of Hi-Tech Pharmacal Co. from an “underperform” rating to a “neutral” rating in a research note to investors on Tuesday, September 10th. They now have a $44.10 price target on the stock. Separately, analysts at Thomson Reuters/Verus downgraded shares of Hi-Tech Pharmacal Co. from a “hold” rating to a “sell” rating in a research note to investors on Monday, September 2nd. Finally, analysts at Standpoint Research downgraded shares of Hi-Tech Pharmacal Co. from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, August 27th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. Hi-Tech Pharmacal Co. presently has a consensus rating of “Hold” and a consensus target price of $42.05.
Hi-Tech Pharmacal Co. (NASDAQ:HITK) traded down 0.12% during mid-day trading on Tuesday, hitting $43.06. 98,343 shares of the company’s stock traded hands. Hi-Tech Pharmacal Co. has a one year low of $28.70 and a one year high of $44.33. The stock’s 50-day moving average is $41.72 and its 200-day moving average is $35.97. The company has a market cap of $586.3 million and a price-to-earnings ratio of 39.84.
Hi-Tech Pharmacal Co. (NASDAQ:HITK) last released its earnings data on Monday, September 9th. The company reported $0.44 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.44. The company had revenue of $50.50 million for the quarter, compared to the consensus estimate of $57.78 million. During the same quarter in the previous year, the company posted $0.44 earnings per share. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, analysts predict that Hi-Tech Pharmacal Co. will post $2.29 earnings per share for the current fiscal year.
Hi-Tech Pharmacal Co, Inc (NASDAQ:HITK), is a specialty manufacturer and marketer of prescription, over-the-counter (OTC) and nutritional products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.